Lexington Biosciences Inc. (LXGTF)

[77Port]

Two things. First: as much as I would like to know private information, let’s be clear that LEX cannot and should not share anything which wouldn’t first be published in a press release. Doing otherwise would be illegal and devastating to the entire company. Silence is golden until they learn the actual results of all testing and then they have to share it with everybody simultaneously. They’re plan is late 2018 or early 2019, so we have a ways to go, but we know they’re on track. As uncomfortable as waiting may be, our job is to uncover the hidden story because LEX cannot share it.

Second:
Following my own advice, I’m rethinking the HS revolution. Gopherdat linked to a previously published article which stated LEX’s goal that it “hopes to revolutionize the self-monitoring medical device sector with its new product called HeartSentry.”

The following Japanese mass market company, Omron, makes a lot of BP cuffs. Walk through any major shop like Wal-Mart, Walgreens or CVS and you will see a line-up of BP cuff price points, many/most made by Omron: $49-$99: Omron's BP cuffs

What's also interesting is Omron’s two NEW online pages. One page shows their wireless model which, to my eye, looks remarkably similar to the HS prototype: Omron wireless device.

This next link shows a different cuff company, also looking similar to the HS prototype: Get Cardio.

And Omron’s second new page shows their new “Zero” campaign, about the future of heart health prevention: Omron campaign: Zero heart attacks. Zero strokes.

Clearly, competition involving heart health prevention is speeding up.

LEX received a US patent. [I recall something about a Japanese patent, but I could not find the link. Anybody have anything like that?] A US patent is obviously positive. It’s also a positive sign that across Omron’s website there is not even a whiff of endothelial function. Patent’s can be “improved upon,” allowing a company to copy or even steal another company’s design. LEX, no doubt, is keeping an eye open for such skullduggery.

Also, seen on Omron’s Zero page above, is this truly interesting sentence regarding Omron’s wearable device. It says: “In development. Final specs and pricing will be released once FDA Clearance is received.”

While speculative, could it be there are BP cuff companies lining up for HS licensing and waiting for release?

LEX added this page: Medical explanation regarding endothelial function.

I had not seen this page before, giving this explanation and it’s importance to diagnosis and prevention. Clearly, LEX is expecting people to use their site as an educational resource.

LEX also provides these two statements on their site:
1. "The technology is designed to be developed into a professional product and potentially as a consumer product pending FDA market approval."

2. "The HeartSentry is expected to be a reusable product but may also be marketed as a fee per use business model."

Imagine this: “… may also be marketed as a fee per use business model.”

So, let’s rethink the idea of the HS revolution. Here’s what is assumed. After releasing HS into the wild, world wide medical heart health will quickly mandate endothelial monitoring, meaning all plain BP cuffs worldwide will immediately become obsolete. Replacement won’t happen overnight, but the revolution will have begun.

So, based on prior conversations on this board, let’s not assume licensing will be to a single partner. That’s not revolutionary; that’s old, stale, horse and buggy speed. Old style licensing would be to work with one company which would sell HS in the "normal/old" way with a high price at first and only later at a lower price as the market widens. But that is a bad idea when attempting to save lives. Literally, people will die due to the slowness.

Revolution, on the other hand, is a tide wiping out the old while bringing in the new.

Think DOS, Microsoft, Windows, Internet Explorer, now Google and Android: all of whom give away product in order to capture customers seeking help. Maybe LEX plans to put HS in front of as many people as possible as quickly as possible.

Maybe there’s a low licensing fee which “may also be marketed as a fee per use business model.”

If so, then there are multiple markets. 1. Every company in the world making BP cuffs, monitors, in addition to every wearable company, including cell phone manufactures. 2. Every clinic and hospital in the world could now easily offer a deep BP and Endothelial reading for a "insurance coverable" fee, with LEX receiving a fee each time.

Revolutionary would be to put LEX/HS everywhere in the world all at once.

Not only would LEX/HS make a measurable dent lowering heart attacks around the world, but as the data rolls in with real-time stories of lives saved, the LEX/HS story could become an actual, world wide hero story.

This is a hypothesis. Thoughts?

NOTE: of all relatively recent prior posts, only one spiked my anxiety. A week or so ago, Sabertooth0071 posted this: “Example, Microsoft buy LEX, Microsoft shares are trading in the 100 dollar range. So if you have 1000 shares of LEX you would get 1 share of MSFT.”

That would be a bummer and tremendously anti-climactic. Jisaiah’s follow-up idea of a billion buck buyout sounds better. However, as noted many times on this board, anything is possible in the alternative pennyverse where the laws of financial physics don’t necessarily apply.

As Gopherdat always says, good luck to us all.